Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
ID: 348995Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348995

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-026.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) focused on schizophrenia and related disorders occurring in mid- to late-life. The initiative aims to advance understanding of the emergence, trajectory, and outcomes of these conditions, with a particular emphasis on identifying intervention targets and prevention strategies. This research is crucial due to the higher morbidity and disability rates among older adults with schizophrenia, highlighting the need for targeted studies to address their unique challenges. Interested applicants can request up to $275,000 in direct costs over two years, with applications due by October 16, 2023, and the funding opportunity remaining open until September 8, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-026.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-026-Full-Announcement.html
    PAR-24-026.html
    The Department of Health and Human Services (HHS) is issuing a Notice of Funding Opportunity (NOFO) for exploratory research grants (R21) focused on schizophrenia and related disorders occurring in mid- to late-life. This funding aims to advance understanding of these conditions' emergence, trajectory, and outcomes, emphasizing the identification of intervention targets and prevention strategies. This initiative invites diverse research teams, particularly those incorporating lived experience insights, to explore biological, psychosocial, and environmental mechanisms affecting older adults with schizophrenia. The total direct costs for projects can reach up to $275,000 over two years, and applications will be reviewed based on scientific merit, innovation, and the investigators’ qualifications. Key dates include an application due date of October 16, 2023, and the funding opportunity expires on September 08, 2026. This research is vital given the higher morbidity and disability among individuals with schizophrenia in this age group, stressing the need for targeted studies to address unique challenges faced by this population.
    Similar Opportunities
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research on schizophrenia and related disorders in individuals aged 35 and older, through the R21 grant mechanism. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors, as well as potential interventions. The funding, which can reach up to $275,000 over a maximum of two years, is crucial for addressing health disparities faced by older adults with these disorders and promoting novel solutions for their care. Applications are due between January 2025 and October 2026, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life," aimed at advancing research on the emergence and trajectory of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to identify biological, psychosocial, and environmental mechanisms affecting this population to develop effective prevention and treatment strategies, addressing a critical gap in mental health research. The funding utilizes the R01 grant mechanism, with applications accepted starting January 5, 2025, and a project period of up to five years. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. The application deadline is September 7, 2026.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Social Disconnection and Suicide Risk in Late Life," aimed at exploring the relationship between social isolation and suicide risk among older adults. This initiative encourages research projects that investigate neurobiological and environmental mechanisms linking social disconnection and loneliness to increased suicidal thoughts and behaviors, with a focus on developing interventions to enhance social connections and prevent suicide in late life. Given the rising suicide rates in this demographic, the NIH emphasizes the urgent need for targeted research, particularly addressing disparities across various populations. Selected projects may receive funding of up to $275,000 over two years, with applications accepted starting January 2025 and a submission deadline of September 7, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-066.html.
    Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Social Disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)" aimed at supporting research on the relationship between social disconnection and suicide risk among older adults. This initiative seeks innovative projects that explore neurobiological, behavioral, and environmental mechanisms influencing social isolation and its impact on suicidal thoughts and behaviors, with an emphasis on promoting health equity and developing interventions to enhance social support. The grant provides a maximum funding amount of $275,000 over a two-year period, with applications due by September 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)" aimed at advancing research on mood and psychotic disorders experienced by women during menopause. This initiative seeks to support translational research that explores the neurobiological and behavioral mechanisms underlying these disorders, with a focus on identifying innovative treatment targets and encouraging interdisciplinary collaboration among researchers. The total funding available for this grant is up to $275,000 for a maximum project period of two years, with applications due by January 7, 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-282.html.